Primary study · included by 1 review
Clinical and radiographic assessment of mineral trioxide aggregate with platelet rich fibrin as pulp capping biomaterials: a 12-month randomized trial.
Abuhashema, 2025 · Abuhashema Rahma Ahmed Ibrahem Hafiz, Essa Mona El Saied, Ibrahim Shereen Hafez, et al. · Scientific reports · 2025
Included by
| Outcome this study informs | Pooled effect | Evidence | Certainty |
|---|---|---|---|
Clinical success (absence of symptoms, abnormal responses and radiographic signs) Platelet-rich fibrin (PRF), alone or combined with other materials vs Mineral trioxide aggregate (MTA) · 12 months | OR 1.51 [0.94, 2.43] | 7 studies · 392 participants | GRADE not reported |
Clinical success (absence of symptoms, abnormal responses and radiographic signs) Platelet-rich fibrin (PRF), alone or combined with other materials vs Mineral trioxide aggregate (MTA) · 12 months | OR 1.5 [0.93, 2.43] | 7 studies · 392 participants | Low |
Clinical success (absence of symptoms, abnormal responses and radiographic signs) Platelet-rich fibrin (PRF), alone or combined with other materials vs Mineral trioxide aggregate (MTA) · 6 months | OR 0.77 [0.44, 1.34] | 7 studies · 436 participants | GRADE not reported |
Clinical success (absence of symptoms, abnormal responses and radiographic signs) Platelet-rich fibrin (PRF), alone or combined with other materials vs Mineral trioxide aggregate (MTA) · 6 months | OR 0.72 [0.29, 1.78] | 7 studies · 436 participants | Low |
1 including review in total.